Browsing by Author "Prat, Aleix"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
    (2013) Li, Shunqiang; Shen, Dong; Shao, Jieya; Crowder, Robert; Liu, Wenbin; Prat, Aleix; He, Xiaping; Liu, Shuying; Hoog, Jeremy; Sánchez Rojel, César Giovanni; Lu, Charles
  • Thumbnail Image
    Item
    Hormone receptor-positive early breast cancer in young women: A comprehensive review
    (2024) Walbaum García, Benjamín Vicente; García-Fructuoso, Isabel; Martínez-Sáez, Olga; Schettini, Francesco; Sánchez Rojel, César Giovanni; Acevedo Claros, Francisco Nicolás; Chic, Nuria; Muñoz-Carrillo, Javier; Adamo, Barbara; Muñoz, Montserrat; Partridge, Ann H.; Bellet, Meritxell; Brasó-Maristany, Fara; Prat, Aleix; Vidal Losada, Maria
    The incidence of breast cancer in ≤ 40 yr-old women (YWBC) has been steadily increasing in recent decades. Although this group of patients represents less than 10 % of all newly diagnosed BC cases it encompasses a significant burden of disease. Usually underrepresented in clinical trials, YWBCs are also characterized by late diagnoses and poorly differentiated, aggressive-subtype disease, partly explaining its poor prognosis along with a high recurrence risk, and high mortality rates. On the other hand, YWBC treatment poses unique challenges such as preservation of fertility, and long-term toxicity and adverse events. Herein, we summarize the current evidence in hormone receptor-positive YWBC including specific risk factors, clinicopathologic and genomic features, and available evidence on response to chemotherapy and endocrine therapy. Overall, we advocate for a more comprehensive multidisciplinary healthcare model to improve the outcomes and the quality of life of this subset of younger patients.